Purso Group expands and strengthens its market position in Europe by acquiring the Dutch company Nedal Aluminium
Purso Group Oy, based in Nokia, Finland, has bought the share capital of the Dutch company Nedal Aluminium B.V. in the largest company acquisition of its history. Purso Oy processes aluminium into profiles and components as well as building and lighting systems. The transaction doubles Purso’s production capacity and opens new markets in Central Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190104005166/en/
Purso Group expands and strengthens its market position in Europe by acquiring the Dutch company Nedal Aluminium
In the transaction, Purso is buying the subsidiary Nedal Aluminium from the listed Dutch company Hunter Douglas. Nedal Aluminium focuses on the high-quality manufacturing of mostly large aluminium profiles in particular and has a production plant in Utrecht, the Netherlands. The transaction price will not be made public.
Last year, the turnover of Nedal Aluminium B.V. was approximately EUR 75 million, and the company has approximately 200 employees. The production plant in Utrecht comprises three extrusion lines which are used for manufacturing of particularly large and heavy profiles. In addition of its extrusion activities Nedal is a main manufacturer of aluminium lighting columns.
“Combining the expertise of two traditional aluminum processors”
“The transaction brings together the expertise of two traditional aluminum processors when Purso, 60 years, initiates a partnership with the 80-year-old Nedal. Besides doubling our production capacity, this transaction helps us strengthen and expand our market reach significantly towards Central Europe in accordance with our strategy,” says Jussi Aro, CEO of Purso Oy, summing up the benefits of the transaction.
“Our two aluminium extrusion lines in Nokia have been fully loaded for a while now, so we have been thinking about different possibilities for increasing the capacity. The Nedal transaction provides the necessary additional capacity and expands our product range towards larger aluminium profiles.”
“Domestic production will not be moved to the Netherlands through the transaction. Our factories in Finland are known for very refined further processing, so it is entirely possible that aluminium profiles manufactured by Nedal in the Netherlands will also be processed in Finland in the future,” Jussi Aro adds.
Nedal continues in Purso Group as a separate company
Nedal Aluminium B.V. continues operating as a separate, independent company in the Purso Group. Synergy benefits are sought through the acquisition of raw materials and sales functions, for example.
“Both production units continue to focus on manufacturing short-run specialty products instead of volume products. We are also keeping our customer-tailored production model, which has helped us maintain long-term customer relationships,” says Jussi Aro.
“Changing ownership only for the 2nd time in its rich 80 years of history this is a major change to all involved. The search for a new shareholder was a very challenging process, but worth it. The engagement with Purso feels like a warm welcome and has all elements to continue growing both companies into the future”, says Marcel Veldman, Managing Director of Nedal Aluminium. As a niche player Nedal has a strong reputation in the field of large, heavy, lengthier and more complex extrusions in a variety of uncommon alloys. It services a wide range of markets throughout Europe and for certain specific products even beyond that. “Both companies have a very clear focus and that is not to follow the footsteps of classical extruders but to build long standing partnerships with customers adding more value for both. We are excited about the future and proud to join the Purso group”
In 1959, Purso started operating as an anodizing plant for aluminum profiles. Purso Oy and its first aluminum extrusion line started operating in Siuro, Nokia, in 1974. Currently, the Group also comprises Linjapinta Oy, focusing on powder coating, and Purso AluCool Oy, a manufacturer of aluminum cooling elements. The companies’ total turnover in 2018 was over EUR 90 million, and the number of staff is 270. Turnover of Purso Group will be after the acquisition approximately EUR 170 million.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Fishawack continues to build best-in-class service offering with Dudnyk acquisition20.3.2019 16:00:00 EET | Tiedote
Fishawack, a leading independent healthcare communications specialist, is excited to announce its acquisition of Dudnyk, the Philadelphia-based healthcare communications agency. Dudnyk is an award-winning, full-service agency that specializes in creating insight-driven, authentic brand experiences that unite specialty physicians and their patients. They leverage strategic, scientific, and creative capabilities to serve clients in the biotech, pharmaceutical, and medical device industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190320005204/en/ Dudnyk leadership team includes Christopher Tobias, PhD, President; Laurie Bartolomeo, EVP, Creative Director; Drew Desjardins, EVP, Chief Strategy Officer; Annemarie Armstrong, EVP, Director of Client Services; John Kemble, EVP, Creative Producer. (Photo: Business Wire) Fishawack’s goal is to increase the range of healthcare communications services that it can offer to commerc
ExaGrid Nominated in Six Categories for the 2019 Network Computing Awards20.3.2019 15:00:00 EET | Tiedote
ExaGrid ®, a leading provider of intelligent hyperconverged storage for backup, today announced that it has been nominated in six categories for the 2019 Network Computing Awards. ExaGrid has become a finalist for Data Centre Product of the Year, The Return on Investment Award, Hardware Product of the Year, Product of the Year, The Customer Service Award, and Company of the Year. Voting to determine the winner in each category is underway now and closes on April 23. The results will be revealed at an evening award ceremony in London on May 2. ExaGrid’s model EX63000E backup storage appliance with data deduplication is a nominee in four categories. The model provides the largest scale-out system and offers up to a 2PB full backup with an ingest rate of 432TB/hr, which is three times faster than any other backup storage on the market. “We are thrilled to be nominated by IT staff, and recognized by Network Computing, in six prestigious categories this year,” said Bill Andrews, CEO and Pre
Eos Biosciences Issued Patent for New Approach to Shuttle Therapeutics Across the Blood-Brain Barrier to Treat Brain Diseases20.3.2019 14:30:00 EET | Tiedote
Eos Biosciences, Inc. (Eos), a nanomedicines company developing an efficient and versatile nanobiologic particle-based platform technology (Eosomes), announced that the U.S. Patent and Trademark Office has granted Eos Biosciences Patent No. 10,183,078, relating to a novel approach of using HER3-targeted Eosomes as a shuttle system for transporting various classes of therapeutics across the blood-brain barrier for treatment of brain disorders, including brain cancer. The patent is owned by Cedars-Sinai Medical Center and is exclusively licensed to Eos Biosciences. Details of the system will be highlighted in an upcoming manuscript from Lali Medina-Kauwe, PhD, Professor, Department of Biomedical Sciences, Cedars-Sinai. Omar Haffar, Ph.D., Founder, President and Chief Executive Officer, commented, “We’re very excited by the issuance of this pivotal patent and look forward to receiving similar approvals in other countries. This patent adds to Eos’ considerable IP portfolio covering the Eos
Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics20.3.2019 13:45:00 EET | Tiedote
Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc. (NYSE: PFE) announced today that Pfizer has acquired a 15% equity interest in Vivet and secured an exclusive option to acquire all outstanding shares. Pfizer and Vivet will collaborate on the development of VTX-801, Vivet’s proprietary treatment for Wilson disease. Wilson disease is a devastating, rare, chronic, and potentially life-threatening liver disorder of impaired copper transport that causes serious copper poisoning. In patients with Wilson disease, a monogenetic mutation disables the normal copper biliary excretion pathway leading to excess copper accumulation in the liver and other organs including the central nervous system. Untreated, Wilson disease results in various combinations and severity of hepatic (fibrosis and cirrhosis), neurologic and psychiatric symptoms, which can b
Fintech Company Rimilia Appoints Kevin Kimber as CEO20.3.2019 13:00:00 EET | Tiedote
Rimilia, a fintech company helping finance departments simplify the complex, has appointed Kevin Kimber as CEO. The news follows another strong year for Rimilia. In 2018, Rimilia opened offices in Central London and Denver, Colorado in the U.S., and reported significant revenue growth on the previous year. Rimilia was founded in 2008 and its platform, created by finance professionals, uses RPA (robotic process automation) technology to help finance teams fast-track their cash flow by providing clearer information and better control. It has quickly become the industry leader, trusted by a number of global brands from HSBC to DHL and Santander, to provide visibility, improve efficiencies and guarantee cash flow. Rimilia works with any currency, any bank and in any language, and on average delivers 70% cost-savings and an 80% reduction in manual effort to its customers. Kevin joins Rimilia from Eight Roads Ventures (one of Rimilia’s investors), where he was a Venture Partner, advising its
Knopp Biosciences Enters Collaboration with Leading UK Investigators to Commence Phase 2 Clinical Trial of Dexpramipexole in Severe Eosinophilic Asthma20.3.2019 13:00:00 EET | Tiedote
Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with high unmet need, today announced a collaboration with a consortium of leading medical researchers in the United Kingdom to evaluate the ability of Knopp’s lead drug candidate, dexpramipexole, to reduce exacerbations in people with severe eosinophilic asthma. The project is chiefly funded by the National Institute for Health Research (NIHR) and Medical Research Council (MRC) of the UK. The Chief Investigator for the Phase 2 multi-center, 52-week trial is Professor Salman Siddiqui, Professor of Airway Diseases at the University of Leicester and Consultant Respiratory Physician at Leicester’s Hospitals. Dexpramipexole is an orally available small molecule shown to selectively reduce eosinophil levels in multiple clinical trials, including in a Phase 2 study in hypereosinophilic syndrome (HES) and a Phase 2 trial in chr
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme